Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
136. |
ECCT/21/07/06 | GBT132_Inclacumab-Ps 3 Trial A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell… read more |
Principal Investigator(s) 1. Fredrick Asirwa Chite 2. Videlis N Nduba 3. Bernhards Ragama Ogutu Site(s) in Kenya 1. International Cancer Institute (ICI)-… read more |
View |
137. |
ECCT/21/12/07 | GBT 132- Inclacumab Phase 3 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell… read more |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Videlis N Nduba 3. Fredrick Asirwa Chite Site(s) in Kenya 1. Strathmore University Medical Centre (… read more |
View |
138. |
ECCT/22/03/09 | GBT 132-Inclacumub PH3 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease… read more |
Principal Investigator(s) 1. Videlis N Nduba 2. Bernhards Ragama Ogutu 3. Fredrick Asirwa Chite Site(s) in Kenya … read more |
View |
139. |
ECCT/21/05/05 |
The “EMPATHY†Trial A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19. |
Principal Investigator(s) 1. DR LUCAS OTIENO TINA 2. Dr. Bernhards Ragama Ogutu 3. Dr Deborah Chepngeno Langat 4. Dr Videlis Nduba Nduba 5. Dr Janet Oyieko … read more |
View |
140. |
ECCT/21/12/05 | 131 Inclacumab Ph 3 Trial. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease… read more |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Fredrick Asirwa Chite 3. Videlis N Nduba 4. Prof. Jessie N Githanga Site(s) in Kenya… read more |
View |